Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Paradigm Biopharmaceuticals Ltd. ( (AU:PAR) ) has shared an update.
Paradigm Biopharmaceuticals Ltd. announced the cancellation of a prior securities issuance announcement due to the incorrect inclusion of Piggyback options in a bonus issue. This adjustment underscores the company’s commitment to regulatory compliance and precise communication with its stakeholders and the market at large.
More about Paradigm Biopharmaceuticals Ltd.
Paradigm Biopharmaceuticals Ltd. is a company operating in the biopharmaceutical industry, focusing on the development and commercialization of medical therapies. The company primarily concentrates on repurposing existing drugs to treat diseases related to inflammation and pain, catering to a market with significant unmet needs.
YTD Price Performance: 17.78%
Average Trading Volume: 3,620
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $142.1M
For a thorough assessment of PAR stock, go to TipRanks’ Stock Analysis page.
